Literature DB >> 17146731

Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.

Amit Kokate1, Xiaoling Li, Bhaskara Jasti.   

Abstract

Fenretinide is a synthetic retinoid with chemotherapeutic activity against various malignancies. Upon oral administration to animals, fenretinide was found to be incompletely absorbed and excreted primarily in feces. The purpose of this study was to determine the possible reasons for poor oral absorption of fenretinide using Caco-2 cell monolayers. To achieve this purpose, a solid dispersion of fenretinide with Povidone K25 was used. The apparent permeability coefficient (P(app)) of fenretinide across Caco-2 monolayers in the presence of bovine serum albumin (BSA) in the receiver was determined. Apical to basolateral (AP-BL) and basolateral to apical (BL-AP) flux studies were performed to determine the role of an efflux mechanism. In the presence of 4% BSA in the receiver, the P(app) was found to be (8.8 +/- 0.5) x 10(-8) cm/sec. The AP-BL flux increased linearly with an increase in fenretinide concentration (125-640 microM) in the presence of 4% BSA in the receiver. Efflux and paracellular pathways played an insignificant role in the permeability of fenretinide. A significant amount of drug, approximately 13-15% of the initial amount accumulated in the cell membrane. The amount of fenretinide in the donor decreased by 16% over a 3 h period. However, only 0.12% of the initial amount was found in the receiver. Also, the P(app) increased with an increase in plasma protein concentration in the receiver. On the basis of these results, the poor permeability of fenretinide can be attributed to its accumulation in the lipophilic cell membrane and poor partitioning into the receiver medium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17146731     DOI: 10.1007/s10637-006-9026-3

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.651


  30 in total

1.  Effects of protein binding on the placental transfer of propofol in the human dually perfused cotyledon in vitro.

Authors:  Y L He; S Tsujimoto; M Tanimoto; R Okutani; K Murakawa; C Tashiro
Journal:  Br J Anaesth       Date:  2000-08       Impact factor: 9.166

2.  Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.

Authors:  Takashi Nozawa; Kozue Imai; Jun-Ichi Nezu; Akira Tsuji; Ikumi Tamai
Journal:  J Pharmacol Exp Ther       Date:  2003-11-10       Impact factor: 4.030

3.  High lipophilicity decreases drug transport across intestinal epithelial cells.

Authors:  P Wils; A Warnery; V Phung-Ba; S Legrain; D Scherman
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

4.  Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.

Authors:  U Veronesi; L Mariani; A Decensi; F Formelli; T Camerini; R Miceli; M G Di Mauro; A Costa; E Marubini; M B Sporn; G De Palo
Journal:  Ann Oncol       Date:  2006-05-04       Impact factor: 32.976

5.  Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells.

Authors:  S Yamashita; T Furubayashi; M Kataoka; T Sakane; H Sezaki; H Tokuda
Journal:  Eur J Pharm Sci       Date:  2000-05       Impact factor: 4.384

6.  Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants.

Authors:  G A Sawada; C L Barsuhn; B S Lutzke; M E Houghton; G E Padbury; N F Ho; T J Raub
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

7.  Crystallographic studies on complexes between retinoids and plasma retinol-binding protein.

Authors:  G Zanotti; M Marcello; G Malpeli; C Folli; G Sartori; R Berni
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

8.  Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers.

Authors:  Pratik Saha; Jim H Kou
Journal:  Eur J Pharm Biopharm       Date:  2002-11       Impact factor: 5.571

9.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.

Authors:  M Pollard; P H Luckert; M B Sporn
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

10.  Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.

Authors:  B N Swanson; D W Zaharevitz; M B Sporn
Journal:  Drug Metab Dispos       Date:  1980 May-Jun       Impact factor: 3.922

View more
  4 in total

1.  Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.

Authors:  Xiao Wu; Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Maynard P Phelps; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2012-03-06       Impact factor: 4.939

2.  Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.

Authors:  Richard A Graves; Grace A Ledet; Elena Y Glotser; Demaurian M Mitchner; Levon A Bostanian; Tarun K Mandal
Journal:  Eur J Pharm Sci       Date:  2015-04-28       Impact factor: 4.384

3.  Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer.

Authors:  Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Steven P Schwendeman
Journal:  Pharm Res       Date:  2011-06-15       Impact factor: 4.200

4.  Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles.

Authors:  Grace A Ledet; Richard A Graves; Elena Y Glotser; Tarun K Mandal; Levon A Bostanian
Journal:  Int J Pharm       Date:  2014-12-24       Impact factor: 5.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.